Literature DB >> 22658763

Immunosenescence and HIV.

Steven G Deeks1, Eric Verdin, Joseph M McCune.   

Abstract

PURPOSE OF REVIEW: The present review discusses the interplay between HIV infection and other environmental factors (e.g. co-infection with CMV) in the acceleration of the aging process of the immune system, leading to 'immunosenescence.' RECENT
FINDINGS: Basic studies in cell biology demonstrate that replicative senescence is a common pathway of many cell lineages, including those of the immune system, characterized by activation of a unique pro-inflammatory secretory program. In the setting of HIV disease, this process is accelerated, resulting in an immunosuppressed state that diminishes the ability of the immune system to contain virus while at the same time facilitating viral replication and spread. Clinically, these changes result in a lower capacity to respond to new infections as well as an increased frequency of age-associated end-organ disease (e.g. cardiovascular complications, cancer, and neurologic disease).
SUMMARY: Accelerated immunosenescence in the setting of HIV disease is associated with increased morbidity and mortality, prompting the need for more investigation into its causes, diagnosis, and treatment. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22658763     DOI: 10.1016/j.coi.2012.05.004

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  72 in total

Review 1.  Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection.

Authors:  Michael L Freeman; Michael M Lederman; Sara Gianella
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

Review 2.  T-cell aging in rheumatoid arthritis.

Authors:  Cornelia M Weyand; Zhen Yang; Jörg J Goronzy
Journal:  Curr Opin Rheumatol       Date:  2014-01       Impact factor: 5.006

Review 3.  Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.

Authors:  Denise C Hsu; Irini Sereti
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

4.  Characterization of gut microbiota composition in HIV-infected patients with metabolic syndrome.

Authors:  María Jesús Villanueva-Millán; Patricia Pérez-Matute; Emma Recio-Fernández; José-Miguel Lezana Rosales; José-Antonio Oteo
Journal:  J Physiol Biochem       Date:  2019-03-28       Impact factor: 4.158

Review 5.  Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer.

Authors:  John Charles A Lacson; Revery P Barnes; Hossein Bahrami
Journal:  Curr Atheroscler Rep       Date:  2017-04       Impact factor: 5.113

Review 6.  Lung microbiome in human immunodeficiency virus infection.

Authors:  Homer L Twigg; George M Weinstock; Kenneth S Knox
Journal:  Transl Res       Date:  2016-07-18       Impact factor: 7.012

Review 7.  Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low- and middle-income countries in Africa.

Authors:  Clement A Adebamowo; Corey Casper; Kishor Bhatia; Sam M Mbulaiteye; Annie J Sasco; Warren Phipps; Sten H Vermund; Susan E Krown
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

8.  Hearing function in patients living with HIV/AIDS.

Authors:  Amneris E Luque; Mark S Orlando; U-Cheng Leong; Paul D Allen; Joseph J Guido; Hongmei Yang; Hulin Wu
Journal:  Ear Hear       Date:  2014 Nov-Dec       Impact factor: 3.570

9.  Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection.

Authors:  Sulggi A Lee; Elizabeth Sinclair; Vivek Jain; Yong Huang; Lorrie Epling; Mark Van Natta; Curtis L Meinert; Jeffrey N Martin; Joseph M McCune; Steven G Deeks; Michael M Lederman; Frederick M Hecht; Peter W Hunt
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

Review 10.  Cytomegalovirus and HIV: A Dangerous Pas de Deux.

Authors:  Sara Gianella; Scott Letendre
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.